The Companion animal pharmaceuticals market share in 2026 include veterinary drugs and vaccines used to prevent and treat health conditions in pets, including dogs, cats, birds, and other companion animals. These products support parasite control, infection management, pain relief, dermatological treatment, vaccination, and chronic disease care. As pet owners increasingly consider animals part of their families, demand for effective medicines and convenient treatment options is growing. Pharmaceutical companies are responding through product innovation, new approvals, and therapies designed to improve animal health and quality of life.
According to Fortune Business Insights, the global companion animal pharmaceuticals market size was valued at USD 21.38 billion in 2025. The market is projected to grow from USD 22.60 billion in 2026 to USD 38.87 billion by 2034, exhibiting a CAGR of 7.02% during the forecast period. North America dominated the market with a 40.73% share in 2025. Rising pet ownership, increasing spending on veterinary care, and growing demand for preventive treatments are supporting market expansion.
The global companion animal pharmaceuticals market includes established veterinary pharmaceutical manufacturers offering medicines, vaccines, and specialized treatments. The key companies identified by Fortune Business Insights include:
These companies focus on expanding veterinary medicine portfolios, developing new treatment options, and strengthening their market presence through product launches, regulatory approvals, and strategic initiatives. Their offerings address both preventive healthcare and the treatment of conditions requiring ongoing veterinary attention.
Market Drivers